BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $94.00

BridgeBio Pharma (NASDAQ:BBIO) had its target price boosted by JPMorgan Chase & Co. from $89.00 to $94.00 in a research report report published on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other equities analysts have also recently weighed in on BBIO. Wells Fargo & Company upped their price objective on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. HC Wainwright increased their price objective on BridgeBio Pharma from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Oppenheimer lowered their price objective on BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 25th. William Blair initiated coverage on shares of BridgeBio Pharma in a research note on Tuesday. They issued an “outperform” rating for the company. Finally, Leerink Partners boosted their price objective on shares of BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, BridgeBio Pharma presently has an average rating of “Moderate Buy” and an average target price of $83.95.

BridgeBio Pharma Trading Down 4.8%

NASDAQ BBIO opened at $67.98 on Tuesday. The stock has a market capitalization of $13.18 billion, a price-to-earnings ratio of -17.98 and a beta of 1.13. BridgeBio Pharma has a twelve month low of $28.33 and a twelve month high of $84.94. The stock has a 50-day moving average of $73.14 and a 200 day moving average of $65.80.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The business had revenue of $154.18 million during the quarter, compared to the consensus estimate of $150.71 million. During the same quarter in the prior year, the firm posted ($1.40) earnings per share. The company’s revenue for the quarter was up 2521.2% compared to the same quarter last year. Equities analysts predict that BridgeBio Pharma will post -3.67 EPS for the current fiscal year.

Insider Activity at BridgeBio Pharma

In related news, Director Andrea Ellis sold 64,921 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total value of $4,211,425.27. Following the sale, the director owned 18,589 shares in the company, valued at $1,205,868.43. This represents a 77.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Randal W. Scott sold 10,000 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $75.46, for a total value of $754,600.00. Following the transaction, the director owned 11,589 shares in the company, valued at $874,505.94. This trade represents a 46.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 227,095 shares of company stock worth $16,099,240. 18.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

A number of institutional investors have recently bought and sold shares of BBIO. Vanguard Group Inc. lifted its holdings in shares of BridgeBio Pharma by 2.1% in the third quarter. Vanguard Group Inc. now owns 16,832,059 shares of the company’s stock valued at $874,257,000 after purchasing an additional 347,074 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of BridgeBio Pharma by 25.8% during the fourth quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock valued at $841,349,000 after buying an additional 2,259,378 shares in the last quarter. Farallon Capital Management LLC raised its position in BridgeBio Pharma by 9.8% during the fourth quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock valued at $688,292,000 after buying an additional 806,463 shares during the period. Aisling Capital Management LP raised its position in BridgeBio Pharma by 0.4% during the third quarter. Aisling Capital Management LP now owns 6,089,611 shares of the company’s stock valued at $316,294,000 after buying an additional 21,486 shares during the period. Finally, Invesco Ltd. lifted its stake in BridgeBio Pharma by 23.0% in the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock worth $369,547,000 after acquiring an additional 902,648 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Phase 3 FORTIFY interim results for oral BBP-418 showed early, broad and sustained efficacy on ambulation (100MTT, 10MWT), biomarker improvement (CK) and a favorable safety profile; management plans an NDA submission in H1 2026 and a U.S. launch late‑2026/early‑2027. Article Title
• Positive Sentiment: Multiple outlets highlighted the FORTIFY data as potentially delivering the first approved therapy for LGMD2I/R9 — a clear clinical and commercial catalyst if the NDA succeeds. Article Title
• Positive Sentiment: Street support: William Blair initiated coverage with an Outperform/positive stance and other firms maintain bullish price targets (median ~$95), which can underpin investor confidence. Article Title
• Neutral Sentiment: Analyst model updates: HC Wainwright reiterated a Buy and $100 PT but revised near‑term EPS timing — analysts are resetting 2026/2027 cadence as launch assumptions evolve (mixed implications for near‑term EPS). Article Title
• Neutral Sentiment: Institutional activity is mixed: several large funds materially added shares while others trimmed positions in Q4 2025 — this creates two‑way flows and variable liquidity. Article Title
• Negative Sentiment: Significant insider selling: disclosed open‑market sales by multiple senior executives over the past six months (many sales, few/no buys) can spook investors and pressure sentiment. Article Title
• Negative Sentiment: Near‑term estimate revisions: some sell‑side modeling cuts to FY2026 EPS and quarterly forecasts (even from bullish firms) increase uncertainty around short‑term profitability before any product launch. Article Title
• Negative Sentiment: Regulatory and execution risk remains: an NDA filing is planned but approval, labeling, reimbursement and launch timing are not guaranteed — investors often sell into binary clinical/regulatory events to lock gains. (See FORTIFY release above.)

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.